COMMUNIQUÉS West-GlobeNewswire

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union
25/07/2025
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants 1 – compared to 2024-2025 COVID-19 [...]
Cannabix Technologies Annual General and Special Meeting Results
25/07/2025
VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company”) announces the results of its annual general and special meeting of common [...]
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO
25/07/2025
Larry L. Wood to join PROCEPT BioRobotics effective September 2, 2025 Company confirms strong underlying business trends and pre-announces 2Q25 revenue of approximately $79.2 million, representing annual growth of 48% [...]
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements
25/07/2025
Not for dissemination in the United States of America VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Aja Health and Wellness Inc. ("Aja" or the "Company") (TSXV:Aja) announces that it is getting closer [...]
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
24/07/2025
REDWOOD CITY, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Cytokinetics to Announce Second Quarter Results On August 7, 2025
24/07/2025
SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 7, 2025 at 4:00 PM Eastern Time. [...]
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer
24/07/2025
MINNEAPOLIS, July 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the first patient has [...]
Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq
24/07/2025
- Special Meeting of Stockholders to be Held Virtually on September 5, 2025 - - Live Stockholder Fireside Chat to be Scheduled to Answer Frequently Asked Stockholder Questions - - Nasdaq Hearings Panel Meeting Scheduled [...]
Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025
24/07/2025
LONDON, July 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8:30 a.m. Eastern [...]
Treace to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025
PONTE VEDRA, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025
HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, [...]
OPKO Health to Report Second Quarter 2025 Financial Results on July 31
24/07/2025
MIAMI, July 24, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on [...]
Iovance Biotherapeutics to Host Second Quarter and First Half 2025 Financial Results and Corporate Updates Webcast on Thursday, August 7, 2025
24/07/2025
SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
24/07/2025
BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to [...]
Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025
MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative [...]
CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025
24/07/2025
Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference ® (AAIC) 2025 Conference call and webcast to be held [...]
RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025
24/07/2025
ALISO VIEJO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025
24/07/2025
CLEARWATER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and [...]
Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
24/07/2025
ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of [...]

Pages